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doi:10.1016/j.kjms.2010.07.002Abstract Macroprolactinemia is often a cause of misdiagnosis, unnecessary expensive investi-
gation, and unsuitable treatment. The aim of the present study was to investigate the clinical
findings and the concentrations of macroprolactin in patients with hyperprolactinemia in our
region. Eighty-four female hyperprolactinemic patients were screened for macroprolactinemia.
Prolactin was measured by chemiluminesans method on an Immulite 2000 analyzer (Siemens
Health Diagnostics, Deerfield, IL, USA). Recoveries less than or equal to 40% after polyethylene
glycol precipitation were indicative of macroprolactinemia. Clinical features and biochemical
values were compared in true hyperprolactinemic and macroprolactinemic patients. Macropro-
lactinemia was detected in 31 patients (36.9%), with 84 hyperprolactinemic female patients.
Therewas no difference in frequency of galactorrhea and oligomenorrhea/amenorrhea between
the two groups. When we evaluated the clinical features of patients according to prolactin
levels, no significant difference was found between the groups. In conclusion, our initial data
show that no clinical features could reliably differentiate macroprolactinemic from true hyper-
prolactinemic patients, but at least one of these symptoms was present in most macroprolacti-
nemic patients.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
Prolactin is a peptide hormone consisting of 199 amino acids
with three intramolecular disulfide bonds and is secreted
from acidophilic cells of the pituitary gland. Prolactin
synthesized as a prehormone with a molecular weight ofof Biochemistry, Karaelmas
rkey.
o.com (M. Can).
vier Taiwan LLC. All rights reserv26 kDa and proteolytically cleaved to mature polypeptide
(monomeric form) has a molecular weight of 23 kDa [1]. The
physiological effects of prolactin are the development of
the breasts during pregnancy and stimulating lactation in
postpartum women. Hyperprolactinemia has been charac-
terized with galactorrhea, oligomenorrhea or amenorrhea,
and infertility in women, and reduced libido, impotence,
and galactorrhea in men [2,3].
Human serum prolactin circulates in multiple forms of
different molecular sizes, including the biologically anded.
174 M. Can et al.immunologically active monomeric prolactin (little prolactin,
23 kDa) and biologically inactive forms dimeric prolactin
(big prolactin, 50e60 kDa) and tetrameric prolactin (big-big
prolactin, 150e170 kDa) [4]. In normal serum, the major
forms are monomeric prolactin (PRL) (85e95%) and dimeric
PRL (10e15%), and the minor form is tetrameric prolactin
(<1%). Big-big prolactin consists of an antigeneantibody
complex of monomeric prolactineimmunoglobulin G and is
currently defined as macroprolactin [5]. Macroprolactin has
a long half-life in blood compared with normal prolactin
and causes high concentrations of prolactin. Macroprolactin
has limited biological activity in vivo, probably explained
by changes in tertiary structure and the high molecular
mass hindering the complex to cross the capillary walls
[6,7]. Macroprolactinemia is often a cause of misdiagnosis,
unnecessary expensive investigation, and unsuitable
treatment [7,8].
The gold standard method of identifying macroprolactin
by gel filtration chromatography of the serum is a time-,
work-, and cost-intensive method not suited for screening
analysis [9]. Therefore, simpler methods as alternatives to
gel filtration chromatography for the screening of macro-
prolactinemia have been developed, including treatment of
sera with polyethylene glycol (PEG), anti-human immuno-
globulin G, and protein A [9]. The aim of the present study
was to investigate the clinical findings and the concentra-
tions of macroprolactin in patients with hyperprolactinemia
in our region.
Materials and methods
The study included 84 female patients with hyper-
prolactinemia, who were consecutively evaluated at
our institution for the subsequent determination of
macroprolactin. Exclusion criteria included assumption of
hyperprolactinemic drugs and presence of potentially
hyperprolactinemic diseases, such as primary hypothy-
roidism, renal failure, major depression, and polycystic
ovary syndrome. The study was approved by the ethical
committee of our institution, and written informed consent
was obtained from each subject.
Prolactin was measured by chemiluminesans method on
an Immulite 2000 analyzer (Siemens Health Diagnostics,
Deerfield, IL, USA). The reference range was 40e530 mIU/L
in women and 53e360 mIU/L in men. The calibration range
of the assay was up to 3,180 mIU/L, with an analyticalTable 1 Comparison of biochemical and clinical values among
Characteristics Group A (nZ 31
Age, yra 29.4 9.9
Prolactin, mIU/La 1,354.6 1,032.
Post PEG prolactin, mIU/La 269.2 235.3
Asymptomatic patient, % 16.9
Galactorrhea, % 40.9
Oligomenorrhea/amenorrhea, % 68.1
a Data are presented as mean  standard deviation.
Group A: increased prolactin levels with macroprolactin and Group B
NSZ not significant; SDZ standard deviation; PEGZ polyethylene glsensitivity of 3.4 mIU/L. The intra-assay coefficient of
variation (CV) values were 2.8%, 3.6%, 2.3%, and 2.5%, at
the levels of 186.6 mIU/L, 402.6 mIU/L, 466.6 mIU/L, and
1,017 mIU/L. The corresponding interassay CV values were
8.2%, 7.4%, 5.9%, and 6.9%.
A total of 250 mL of serum was added to 250 mL of 25%
PEG 6000 solution (Sigma-Aldrich Inc., Milan, Italy), mixed,
and centrifuged for 30 minutes at 1,400 g at room
temperature. A further 250 mL serum was added to 250 mL
of a sample diluent. Prolactin was measured both in
untreated serum and in the supernatant, and the results
were expressed as percentage of prolactin recovery.
Patients with a recovery less than 40% were classified as
macroprolactinemic.
All statistical calculations were performed using SPSS
version 13.0 for Windows (SPSS Inc., Chicago, IL, USA).
Quantitative variables were reported in the text as
mean standard deviation. Comparison of clinical and
biochemical characteristics was made by the c2 test for
categorical variables and the Students’ paired and
unpaired t tests, ManneWhitney U test, and Krus-
kaleWallis nonparametric analysis of variance for contin-
uous variables. Two-tailed p value less than 0.05 was
considered statistically significant.
Results
Serum samples were obtained from 31 patients with mac-
roprolactinemia (Group A), defined as having hyper-
prolactinemia. A group of hyperprolactinemic patients
(nZ 53) with the absence of macroprolactin was consid-
ered a group of true hyperprolactinemic patients (Group B).
Macroprolactinemia was detected in 31 patients (36.9%),
with 84 hyperprolactinemic female patients. Mean
prolactin in patients with macroprolactinemia was
1,354.6 mIU/L, and in hyperprolactinemic patients without
macroprolactinemia, it was 2,018.2 mIU/L. Galactorrhea
and oligomenorrhea/amenorrhea were more common in
patients with the absence of macroprolactin. There was no
difference in the frequencies of galactorrhea and oligo-
menorrhea/amenorrhea between the two groups (Table 1).
When we evaluate the clinical features of patients
according to the prolactin levels, no significant difference
was found between Group 1 [clinical feature (þ) and
macroprolactin ()] and Group 2 [clinical feature () and
macroprolactin ()] (Fig. 1). There were no significantpatients
) Group B (nZ 53) p
33.0 10.9 NS





: increased prolactin levels in the absence of macroprolactin.
ycol.
Figure 1. Comparison of prolactin levels (mean standard deviation) according to the clinical features. Group 1 Z clinical
feature (þ), macroprolactin (); Group 2 Z clinical feature () macroprolactin (); Group 3 Z clinical feature (þ), macro-
prolactin (þ); Group 4 Z clinical feature (), macroprolactin (þ).
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feature (þ) and macroprolactin (þ)] and Group 4 [clinical
feature () and macroprolactin (þ)] (Fig. 1).
Discussion
Macroprolactin is common in patients with hyper-
prolactinemia, but the incidence of macroprolactinemia is
not known precisely. The incidence of macroprolactinemia
ranges from 10e46% of samples from these patients
[10,11]. Valette-Kasic et al. [10] identified macro-
prolactinemia in 10% of participants with hyper-
prolactinemia, and this low incidence was attributable to
selection bias. Hauache et al. [11] found the highest inci-
dence of macroprolactinemia (46%). The authors attribute
this high incidence to the nature of the study center, which
received samples sent from other laboratories for confir-
mation of results. Vieira et al. [12] found macroprolactin to
be prevalent in 36% of the 1,279 samples with PRL more
than 540 mU/L. In our study, macroprolactin was found at
a frequency of 36.9% of the hyperprolactinemic patients
(>530 mIU/L) based on the limit of less than 40% recovery
after PEG precipitation. In our opinion, this discrepancy in
studies depends on patient selection, threshold for
measuring prolactin, limit of recovery used, and the type of
immunochemical method. Furthermore, the high preva-
lence of macroprolactinemia in our patients might also be
because of the fact that our hospital is a center for unex-
pected hormone results that are sent from other hospitals
for confirmation.
Hyperprolactinemic patients usually have galactorrhea,
menstrual irregularity, and infertility. In our study, 16.9% of
the patients with macroprolactinemia had no symptoms of
hyperprolactinemia. Conversely, 6.4% of the patients with
true hyperprolactinemia were asymptomatic. According to
our results, the occurrence of the symptoms shows
asymptomatic hyperprolactinemia with a predominance of
macroprolactin in the circulation. Biological activity of
macroprolactin is controversial. First reports on macro-
prolactin in the NB2 lymphoma cell bioassay showed lower
biological activity [13], but in recent studies, normal
bioactivity of macroprolactin was shown in the NB2 assay
[14]. Leslie et al. [15] reviewed 55 consecutively presenting
patients with macroprolactinemia and concluded that the
clinical features of hyperprolactinemia were unusual in this
group. Vallette-Kasic et al. [10] found that galactorrhea
and menstrual abnormalities were significantly less
frequently associated in the macroprolactinemic patients
compared with the hyperprolactinemic patients with
a normal PRL chromatography. Suliman et al. [7] reported
that oligomenorrhea and galactorrhea occurred more
frequently in patients with true hyperprolactinemia (84%
and 63%, respectively) than in macroprolactinemic patients
(57% and 29%, respectively). In our data, the clinical find-
ings leading to the diagnosis of macroprolactinemia,
including menstrual disorders and galactorrhea, were
not significantly different from those of true hyper-
prolactinemic patients. Taking these findings into account,
PEG has proved to be a useful reagent in distinguishing
macroprolactinemia from true hyperprolactinemia, but one
should always keep in mind that macroprolactinemicpatients cannot be distinguished from patients with true
hyperprolactinemia on the basis of clinical features alone.
In conclusion, our initial data show that no clinical
features could reliably differentiate macroprolactinemic
from true hyperprolactinemic patients, but at least one of
these symptoms was present in most macroprolactinemic
patients. Also, we recommend screening macro-
prolactinemia in all hyperprolactinemic patients for
avoiding unnecessary further investigations, which would
result in cost saving and accurate diagnosis.References
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